Provided by Tiger Trade Technology Pte. Ltd.

Shuttle Pharmaceuticals Inc

1.71
+0.00500.29%
Volume:29.79K
Turnover:50.92K
Market Cap:2.73M
PE:-0.06
High:1.75
Open:1.75
Low:1.65
Close:1.70
52wk High:25.25
52wk Low:1.26
Shares:1.60M
Float Shares:1.52M
Volume Ratio:0.17
T/O Rate:1.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-27.4938
EPS(LYR):-79.6550
ROE:-27176.19%
ROA:-323.31%
PB:1.96
PE(LYR):-0.02

Loading ...

Company Profile

Company Name:
Shuttle Pharmaceuticals Inc
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
9
Office Location:
401 Professional Drive,Suite 260,Gaithersburg,Maryland,United States
Zip Code:
20879
Fax:
- -
Introduction:
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.

Directors

Name
Position
Anatoly Dritschilo
Chairman of the board and Chief Executive Officer
Adam Chambers
Director
Angel Liriano
Director
George Scorsis
Director
Oleh Nabyt
Director
Sachin Pathigoda
Director

Shareholders

Name
Position
Anatoly Dritschilo
Chairman of the board and Chief Executive Officer
Christopher R. Cooper
Interim Chief Executive Officer and Chief Financial Officer
Mira Jung
Chief Scientific Officer
Tyvin Rich
Chief Clinical Officer